Abstract
The binding of integrin alpha(L)beta(2) to its ligand intercellular adhesion molecule-1 is required for immune responses and leukocyte trafficking. Small molecule antagonists of alpha(L)beta(2) are under intense investigation as potential anti-inflammatory drugs. We describe for the first time a small molecule integrin agonist. A previously described alpha/beta I allosteric inhibitor, compound 4, functions as an agonist of alpha(L)beta(2) in Ca(2+) and Mg(2+)and as an antagonist in Mn(2+). We have characterized the mechanism of activation and its competitive and noncompetitive inhibition by different compounds. Although it stimulates ligand binding, compound 4 nonetheless inhibits lymphocyte transendothelial migration. Agonism by compound 4 results in accumulation of alpha(L)beta(2) in the uropod, extreme uropod elongation, and defective de-adhesion. Small molecule integrin agonists open up novel therapeutic possibilities.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Allosteric Regulation
-
Antibodies, Monoclonal
-
Cations, Divalent / metabolism
-
Cations, Divalent / pharmacology
-
Cell Adhesion / drug effects
-
Cell Movement / drug effects
-
Humans
-
In Vitro Techniques
-
Intercellular Adhesion Molecule-1 / metabolism
-
K562 Cells
-
Lymphocyte Function-Associated Antigen-1 / chemistry
-
Lymphocyte Function-Associated Antigen-1 / drug effects*
-
Lymphocyte Function-Associated Antigen-1 / genetics
-
Lymphocyte Function-Associated Antigen-1 / metabolism
-
Lymphocytes / drug effects
-
Lymphocytes / physiology
-
Molecular Structure
-
Mutation
-
Protein Binding
-
Recombinant Proteins / agonists
-
Recombinant Proteins / chemistry
-
Recombinant Proteins / genetics
-
Recombinant Proteins / metabolism
-
Transfection
Substances
-
Antibodies, Monoclonal
-
Cations, Divalent
-
Lymphocyte Function-Associated Antigen-1
-
Recombinant Proteins
-
Intercellular Adhesion Molecule-1